Repurposing the cystic fibrosis drug ivacaftor as an efflux pump inhibitor to inhibit antimicrobial resistance in Pseudomonas aeruginosa

Pseudomonas aeruginosa : is one of the predominant pathogens associated with cystic fibrosis (CF) airway infections. Treatment is often challenging due to its intrinsic multidrug resistance, particularly because of the activity of tripartite resistance–nodulation–division (RND) drug efflux pumps such as the MexAB–OprM system. We have previously shown that ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator used in CF therapy, could enhance antibiotic activity against Escherichia coli through inhibition of the AcrB drug efflux protein. Given the high level of homology between the resistance-nodulation-division (RND) transporters from the drug efflux complexes, AcrB and MexB, the aim of this study was to investigate if ivacaftor could also synergise with antibiotics used to treat Pseudomonas aeruginosa infections in people with cystic fibrosis. Molecular dynamics simulation interrogated the interaction between ivacaftor and MexB. Thermal shift analysis and surface plasmon resonance were employed to determine the affinity of ivacaftor binding to MexB. The effects of ivacaftor on antibiotic susceptibility, efflux activity, and membrane integrity were investigated for reference strains and clinical P. aeruginosa strains isolated from people with CF. Our results predicted binding of ivacaftor to the distal binding site of MexB. Ivacaftor interacted with the RND transporters AcrB and MexB with a similar affinity as the efflux pump inhibitor (EPI) phenylalanine-arginine beta-naphthylamide (PAβN). Checkerboard assays demonstrated that ivacaftor restored susceptibility to several antibiotics currently used in anti-pseudomonal CF therapy, particularly aztreonam, ceftazidime, ciprofloxacin, and meropenem, while enhancing the antibiotic activity of azithromycin, erythromycin and minocycline. Nile Red efflux and Hoechst 33342 accumulation assays further supported inhibition of efflux activity by ivacaftor. Ivacaftor did not produce any off-target effects on the bacterial inner- or outer membrane. Overall, the results suggest that ivacaftor can function as an EPI in P. aeruginosa, thereby enhancing antibiotic activity. These findings support further investigation of CFTR modulators as adjunctive therapies against chronic infections caused by multidrug-resistant P. aeruginosa.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-12
DOI
https://doi.org/10.3389/fphar.2026.1979931
Primary Topic
Antibiotic Resistance in Bacteria
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Repurposing the cystic fibrosis drug ivacaftor as an efflux pump inhibitor to inhibit antimicrobial resistance in Pseudomonas aeruginosa

Steven W. Polyak, Henrietta Venter, Utid Suriya, Susan J. Semple et al.
Frontiers in Pharmacology
Antibiotic Resistance in Bacteria
article

Repurposing the cystic fibrosis drug ivacaftor as an efflux pump inhibitor to inhibit antimicrobial resistance in Pseudomonas aeruginosa

Steven W. Polyak, Henrietta Venter, Utid Suriya, Susan J. Semple, Matthew Phanchana, Sylvia A. Sapula, Yang Chen, Judith M. Morton, Hanbiao Chen, Sida Liu
article en

Abstract

Pseudomonas aeruginosa : is one of the predominant pathogens associated with cystic fibrosis (CF) airway infections. Treatment is often challenging due to its intrinsic multidrug resistance, particularly because of the activity of tripartite resistance–nodulation–division (RND) drug efflux pumps such as the MexAB–OprM system. We have previously shown that ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator used in CF therapy, could enhance antibiotic activity against Escherichia coli through inhibition of the AcrB drug efflux protein. Given the high level of homology between the resistance-nodulation-division (RND) transporters from the drug efflux complexes, AcrB and MexB, the aim of this study was to investigate if ivacaftor could also synergise with antibiotics used to treat Pseudomonas aeruginosa infections in people with cystic fibrosis. Molecular dynamics simulation interrogated the interaction between ivacaftor and MexB. Thermal shift analysis and surface plasmon resonance were employed to determine the affinity of ivacaftor binding to MexB. The effects of ivacaftor on antibiotic susceptibility, efflux activity, and membrane integrity were investigated for reference strains and clinical P. aeruginosa strains isolated from people with CF. Our results predicted binding of ivacaftor to the distal binding site of MexB. Ivacaftor interacted with the RND transporters AcrB and MexB with a similar affinity as the efflux pump inhibitor (EPI) phenylalanine-arginine beta-naphthylamide (PAβN). Checkerboard assays demonstrated that ivacaftor restored susceptibility to several antibiotics currently used in anti-pseudomonal CF therapy, particularly aztreonam, ceftazidime, ciprofloxacin, and meropenem, while enhancing the antibiotic activity of azithromycin, erythromycin and minocycline. Nile Red efflux and Hoechst 33342 accumulation assays further supported inhibition of efflux activity by ivacaftor. Ivacaftor did not produce any off-target effects on the bacterial inner- or outer membrane. Overall, the results suggest that ivacaftor can function as an EPI in P. aeruginosa, thereby enhancing antibiotic activity. These findings support further investigation of CFTR modulators as adjunctive therapies against chronic infections caused by multidrug-resistant P. aeruginosa.

Frontiers in PharmacologyVol. 17
Royal Adelaide Hospital (AU), Mahidol University (TH), Adelaide University (AU), The University of Adelaide (AU)
National Health and Medical Research Council
Good health and well-being
Antibiotic Resistance in Bacteria
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon